Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) trades at $60.84 with AI Score 47/100 (Grade C). Eventide Healthcare & Life Sciences Fd Cl I is a mutual fund focused on long-term capital… Market cap: $1.95B, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ETIHX: ETIHX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ETIHX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ETIHX: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) Financial Services Profile
Eventide Healthcare & Life Sciences Fd Cl I is a mutual fund specializing in equity and equity-related securities within the healthcare and life sciences sectors. The fund invests across market capitalizations and geographies, including ADRs, aiming for long-term capital appreciation. It operates within the competitive asset management industry.
What Is the Investment Thesis for ETIHX?
Eventide Healthcare & Life Sciences Fd Cl I presents an investment opportunity within the growing healthcare and life sciences sectors. The fund's focus on long-term capital appreciation aligns with the potential for innovation and growth within these industries. A key value driver is the fund's ability to invest across market capitalizations and geographies, providing diversification and access to a broader range of investment opportunities. The fund's investment in ADRs allows it to tap into international markets. Potential risks include market volatility and sector-specific risks associated with the healthcare and life sciences industries. The fund's performance is also dependent on the expertise of its investment management team and their ability to identify and capitalize on investment opportunities. The fund's beta of 1.27 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
ETIHX Key Highlights
The fund invests at least 80% of its net assets in equity and equity-related securities of companies in the healthcare and life sciences sectors.
- The fund can invest without limitation in securities of companies domiciled outside the United States, either directly or through American Depositary Receipts (ADRs).
- The fund may invest in securities of companies of any market capitalization.
- The fund's objective is to provide long-term capital appreciation.
- The fund has a market capitalization of $1.95B.
Who Are ETIHX's Competitors?
ETIHX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BAUAX Brown Advisory Small-Cap Fundamental Value Fund Advisor Shs | $31.61 | -0.85% | $1.18B | 44 |
| CVMAX Calvert Emerging Markets Equity Fund Class A | $28.57 | +0.81% | $1.74B | 47 |
| HAVLX Harbor Large Cap Value Fund Institutional Class | $20.88 | -1.18% | $985M | 46 |
| JOEAX JOHCM Emerging Markets Opportunities Fund - Investor Shares | $17.32 | +1.35% | $1.67B | 53 |
| NEFJX Natixis Funds Trust I Vaughan Nelson Small Cap Value Fund | $22.71 | -0.74% | $1.49B | 46 |
| TSLX Sixth Street Specialty Lending, Inc. | $18.77 | +0.37% | $1.78B | 68 |
| CET Central Securities Corp. | $54.21 | -0.90% | $1.60B | 70 |
| GCMG GCM Grosvenor Inc. | $13.47 | -2.25% | $2.52B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ETIHX's Key Strengths?
Specialized focus on the healthcare and life sciences sectors.
- Ability to invest across market capitalizations and geographies.
- Access to international markets through ADRs.
- Objective of long-term capital appreciation.
What Are ETIHX's Weaknesses?
Sector-specific focus may limit diversification.
- Performance is dependent on the healthcare and life sciences sectors.
- Subject to market volatility and sector-specific risks.
- No dividend yield.
What Could Drive ETIHX Stock Higher?
Innovation and advancements in healthcare and life sciences technologies.
- Increasing healthcare spending in emerging markets.
- Aging global population driving demand for healthcare services.
- Potential regulatory changes and healthcare policy reforms.
What Are the Key Risks for ETIHX?
Market volatility and economic downturns.
- Sector-specific risks associated with healthcare and life sciences.
- Regulatory changes and healthcare policy risks.
- Competition from other asset management firms.
- Drug development and clinical trial risks.
What Are the Growth Opportunities for ETIHX?
- Expansion into Emerging Markets: The increasing healthcare spending in emerging markets presents a significant growth opportunity for the fund. As these economies develop, their healthcare infrastructure and demand for advanced medical treatments are expected to grow, creating opportunities for investments in local healthcare and life sciences companies. The fund's ability to invest in companies domiciled outside the United States, including through ADRs, positions it to capitalize on this trend. This expansion could contribute to higher returns and diversification of the fund's portfolio, with a potential timeline of 3-5 years.
- Increased Investment in Biotechnology: The biotechnology industry is experiencing rapid innovation, with new therapies and technologies being developed at an accelerated pace. By increasing its investment in biotechnology companies, the fund can tap into the potential for high growth and returns. This strategy aligns with the fund's objective of long-term capital appreciation and can benefit from the increasing demand for innovative healthcare solutions. The timeline for realizing the benefits of this growth opportunity is estimated to be 2-4 years, given the dynamic nature of the biotechnology industry.
- Focus on Personalized Medicine: The rise of personalized medicine, which tailors medical treatment to individual patients based on their genetic makeup and other factors, presents a significant growth opportunity. By investing in companies that are developing and commercializing personalized medicine technologies, the fund can capitalize on this trend. This approach aligns with the increasing focus on precision healthcare and the potential for more effective and targeted treatments. The timeline for this growth opportunity is projected to be 3-5 years, as personalized medicine becomes more widely adopted.
- Growing Demand for Healthcare Services: The aging global population and increasing prevalence of chronic diseases are driving the demand for healthcare services. By investing in companies that provide healthcare services, such as hospitals, clinics, and home healthcare providers, the fund can benefit from this long-term trend. This strategy aligns with the increasing need for accessible and affordable healthcare services and the potential for stable and consistent returns. The timeline for this growth opportunity is estimated to be 5-10 years, given the demographic trends and the increasing demand for healthcare services.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other investment firms, research institutions, and healthcare organizations can enhance the fund's investment capabilities and access to deal flow. These partnerships can provide the fund with valuable insights, expertise, and access to investment opportunities that it may not otherwise have. This collaborative approach can also help the fund to mitigate risks and improve its overall performance. The timeline for realizing the benefits of this growth opportunity is estimated to be 1-3 years, as partnerships are established and collaborations are implemented.
What Are ETIHX's Competitive Advantages?
- Specialized focus on the healthcare and life sciences sectors.
- Ability to invest across market capitalizations and geographies.
- Access to international markets through ADRs.
What Does ETIHX Do?
Eventide Healthcare & Life Sciences Fd Cl I is a mutual fund with the stated objective of achieving long-term capital appreciation. The fund focuses its investments primarily within the healthcare and life sciences sectors. Under normal market conditions, the fund allocates at least 80% of its net assets, plus borrowings for investment purposes, into equity and equity-related securities of companies operating in these sectors. These securities include common stock, options, preferred stock, and convertible debt. The fund's investment strategy is not limited by geography, as it may invest in securities of companies domiciled outside the United States, either directly or through American Depositary Receipts (ADRs). This global approach allows the fund to tap into growth opportunities in the international healthcare and life sciences markets. Furthermore, the fund is not restricted by market capitalization, enabling it to invest in companies of all sizes, from small-cap to large-cap. Eventide Healthcare & Life Sciences Fd Cl I operates within the asset management industry, offering investors a specialized investment vehicle focused on the healthcare and life sciences sectors. The fund competes with other mutual funds and investment firms that offer similar sector-specific investment products.
What Products and Services Does ETIHX Offer?
- Invests in equity and equity-related securities.
- Focuses on companies in the healthcare and life sciences sectors.
- Invests in common stock, options, preferred stock, and convertible debt.
- Invests in companies of any market capitalization.
- May invest in securities of companies domiciled outside the United States.
- May invest through American Depositary Receipts (ADRs).
How Does ETIHX Make Money?
- Generates revenue through investment management fees.
- Aims to provide long-term capital appreciation for investors.
- Allocates capital to companies in the healthcare and life sciences sectors.
What Industry Does ETIHX Operate In?
Eventide Healthcare & Life Sciences Fd Cl I operates within the asset management industry, specifically focusing on the healthcare and life sciences sectors. The asset management industry is characterized by intense competition, with numerous firms offering a wide range of investment products and strategies. The healthcare and life sciences sectors are driven by factors such as an aging global population, advancements in medical technology, and increasing healthcare spending. These sectors are also subject to regulatory scrutiny and potential risks associated with drug development and clinical trials. The fund's performance is influenced by the overall market trends and the performance of the healthcare and life sciences sectors.
Who Are ETIHX's Key Customers?
- Individual investors seeking exposure to the healthcare and life sciences sectors.
- Institutional investors looking for long-term capital appreciation.
- Retirement savers seeking diversified investment options.
ETIHX Valuation & Market Position
With a $1.95B market cap, Eventide Healthcare & Life Sciences Fd Cl I sits in the small-cap segment of the market. Relative to its peer group, ETIHX's quantitative score of 47/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for Eventide Healthcare & Life Sciences Fd Cl I stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. ETIHX trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
ETIHX Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Eventide's long-term strategy within the healthcare sector.
- Community sentiment reflects optimism about Eventide's ethical investment approach resonating with a growing segment of investors.
- The fund's focus on healthcare and life sciences aligns with long-term demographic trends and innovation in the industry.
- Market perception indicates a positive view of Eventide's commitment to socially responsible investing, attracting values-driven capital.
Bear Case
- Increased volatility in the healthcare sector could negatively impact Eventide's portfolio performance.
- Bearish community views express concern over potential regulatory changes affecting the pharmaceutical and biotech industries.
- Market perception suggests potential headwinds due to rising interest rates impacting growth stocks within the portfolio.
- Recent market developments indicate increased competition among socially responsible investment funds, potentially diluting Eventide's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ETIHX Latest News
No recent news available for ETIHX.
ETIHX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ETIHX.
Price Targets
Wall Street price target analysis for ETIHX.
ETIHX MoonshotScore
What does this score mean?
The MoonshotScore rates ETIHX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
ETIHX Financial Services Stock FAQ
What does the AI Score mean for ETIHX?
ETIHX holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Eventide Healthcare & Life Sciences Fd Cl I is a mutual fund focused on long-term capital appreciation through investments in the healthcare and life sciences sectors. The fund invests in both …
What does Eventide Healthcare & Life Sciences Fd Cl I do?
Eventide Healthcare & Life Sciences Fd Cl I is a mutual fund that focuses on providing long-term capital appreciation by investing primarily in equity and equity-related securities of companies within the healthcare and life sciences sectors. The fund invests across various market capitalizations and geographies, including international markets through American Depositary Receipts (ADRs).
What are the main risks for ETIHX?
The main risks for ETIHX include market volatility, sector-specific risks associated with the healthcare and life sciences industries, regulatory changes, and competition from other asset management firms. The fund's performance is dependent on the overall market conditions and the performance of the healthcare and life sciences sectors. Regulatory changes and healthcare policy reforms can also impact the fund's investments.
How sensitive is ETIHX to changes in healthcare regulations and policies?
ETIHX's performance is significantly influenced by changes in healthcare regulations and policies, given its focus on the healthcare and life sciences sectors. Changes in drug pricing regulations, FDA approval processes, and healthcare reimbursement policies can have a material impact on the profitability and growth prospects of companies within the fund's portfolio.
What is Eventide Healthcare & Life Sciences Fd Cl I's approach to managing risk within the healthcare and life sciences sectors?
Eventide Healthcare & Life Sciences Fd Cl I manages risk within the healthcare and life sciences sectors through diversification across various sub-sectors, market capitalizations, and geographies. The fund's investment strategy involves a thorough analysis of companies' financial performance, competitive positioning, and regulatory environment.
What are the key factors to evaluate for ETIHX?
Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) holds an AI score of 47/100 (low). Eventide Healthcare & Life Sciences Fd Cl I presents an investment opportunity within the growing healthcare and life sciences sectors. Not financial advice.
How frequently does ETIHX data refresh on this page?
ETIHX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ETIHX's recent stock price performance?
Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on the healthcare and life sciences sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ETIHX overvalued or undervalued right now?
Eventide Healthcare & Life Sciences Fd Cl I (ETIHX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on the available data and may be subject to change.
- AI analysis is pending for ETIHX.